83 related articles for article (PubMed ID: 1493453)
1. A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin's disease at diagnosis. The Scotland and Newcastle Lymphoma Group (SNLG) Therapy Working Party.
Proctor SJ; Taylor P; Mackie MJ; Donnan P; Boys R; Lennard A; Prescott RJ
Leuk Lymphoma; 1992; 7 Suppl():17-20. PubMed ID: 1493453
[TBL] [Abstract][Full Text] [Related]
2. A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin's disease at diagnosis. Scotland and Newcastle Lymphoma Group (SNLG) Therapy Working Party.
Proctor SJ; Taylor P; Donnan P; Boys R; Lennard A; Prescott RJ
Eur J Cancer; 1991; 27(5):624-9. PubMed ID: 1828974
[TBL] [Abstract][Full Text] [Related]
3. A population-based study of intensive multi-agent chemotherapy with or without autotransplant for the highest risk Hodgkin's disease patients identified by the Scotland and Newcastle Lymphoma Group (SNLG) prognostic index. A Scotland and Newcastle Lymphoma Group study (SNLG HD III).
Proctor SJ; Mackie M; Dawson A; White J; Prescott RJ; Lucraft HL; Angus B; Jackson GH; Lennard AL; Hepplestone A; Taylor PR
Eur J Cancer; 2002 Apr; 38(6):795-806. PubMed ID: 11937314
[TBL] [Abstract][Full Text] [Related]
4. Early high dose chemotherapy intensification with autologous bone marrow transplantation in lymphoma associated with retention of fertility and normal pregnancies in females. Scotland and Newcastle Lymphoma Group, UK.
Jackson GH; Wood A; Taylor PR; Lennard AL; Lucraft H; Heppleston A; Robinson P; Moore J; Proctor SJ
Leuk Lymphoma; 1997 Dec; 28(1-2):127-32. PubMed ID: 9498711
[TBL] [Abstract][Full Text] [Related]
5. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP
Borchmann P; Haverkamp H; Lohri A; Mey U; Kreissl S; Greil R; Markova J; Feuring-Buske M; Meissner J; Dührsen U; Ostermann H; Keller U; Maschmeyer G; Kuhnert G; Dietlein M; Kobe C; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Engert A
Lancet Oncol; 2017 Apr; 18(4):454-463. PubMed ID: 28236583
[TBL] [Abstract][Full Text] [Related]
6. Prognosis of patients with advanced Hodgkin's disease: evaluation of four prognostic models using 344 patients included in the Group d'Etudes des Lymphomes de l'Adulte Study.
Fermé C; Bastion Y; Brice P; Lederlin P; Diviné M; Gabarre J; Assouline D; Ferrant A; Berger F; Lepage E
Cancer; 1997 Sep; 80(6):1124-33. PubMed ID: 9305714
[TBL] [Abstract][Full Text] [Related]
7. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group.
Josting A; Franklin J; May M; Koch P; Beykirch MK; Heinz J; Rudolph C; Diehl V; Engert A
J Clin Oncol; 2002 Jan; 20(1):221-30. PubMed ID: 11773173
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Factors and a New Prognostic Index Model for Children and Adolescents with Hodgkin's Lymphoma Who Underwent Autologous Hematopoietic Stem Cell Transplantation: A Multicenter Study of the Turkish Pediatric Bone Marrow Transplantation Study Group.
Kesik V; Ataş E; Karakükcü M; Aksoylar S; Erbey F; Taçyıldız N; Küpesiz A; Öniz H; Ünal E; Kansoy S; Öztürk G; Elli M; Kaya Z; Ünal E; Hazar V; Yılmaz Bengoa Ş; Karasu G; Atay D; Dağdemir A; Ören H; Koçak Ü; Yeşilipek MA
Turk J Haematol; 2016 Dec; 33(4):265-272. PubMed ID: 27094103
[TBL] [Abstract][Full Text] [Related]
9. Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR).
Lazarus HM; Loberiza FR; Zhang MJ; Armitage JO; Ballen KK; Bashey A; Bolwell BJ; Burns LJ; Freytes CO; Gale RP; Gibson J; Herzig RH; LeMaistre CF; Marks D; Mason J; Miller AM; Milone GA; Pavlovsky S; Reece DE; Rizzo JD; van Besien K; Vose JM; Horowitz MM
Bone Marrow Transplant; 2001 Feb; 27(4):387-96. PubMed ID: 11313668
[TBL] [Abstract][Full Text] [Related]
10. The identification of discrete prognostic groups in low grade non-Hodgkin's lymphoma. The Scotland and Newcastle Lymphoma Group Therapy Working Party.
Leonard RC; Hayward RL; Prescott RJ; Wang JX
Ann Oncol; 1991 Oct; 2(9):655-62. PubMed ID: 1742221
[TBL] [Abstract][Full Text] [Related]
11. [Clinical features, treatment and prognosis of 136 patients with primary non-Hodgkin's lymphoma of the nasopharynx].
Yuan ZY; Li YX; Zhao LJ; Gao YH; Liu XF; Gu DZ; Qian TN; Yu ZH
Zhonghua Zhong Liu Za Zhi; 2004 Jul; 26(7):425-9. PubMed ID: 15355649
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease.
Jagannath S; Armitage JO; Dicke KA; Tucker SL; Velasquez WS; Smith K; Vaughan WP; Kessinger A; Horwitz LJ; Hagemeister FB
J Clin Oncol; 1989 Feb; 7(2):179-85. PubMed ID: 2644397
[TBL] [Abstract][Full Text] [Related]
13. High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation. Lymphoma Working Party.
Sweetenham JW; Carella AM; Taghipour G; Cunningham D; Marcus R; Della Volpe A; Linch DC; Schmitz N; Goldstone AH
J Clin Oncol; 1999 Oct; 17(10):3101-9. PubMed ID: 10506605
[TBL] [Abstract][Full Text] [Related]
14. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes.
Wheeler C; Eickhoff C; Elias A; Ibrahim J; Ayash L; McCauley M; Mauch P; Schwartz G; Eder JP; Mazanet R; Ferrara J; Rimm IJ; Guinan E; Bierer B; Gilliland G; Churchill WH; Ault K; Parsons S; Antman K; Schnipper L; Tepler I; Gaynes L; Frei E; Kadin M; Antin J
Biol Blood Marrow Transplant; 1997 Jun; 3(2):98-106. PubMed ID: 9267670
[TBL] [Abstract][Full Text] [Related]
15. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease.
Hasenclever D; Diehl V
N Engl J Med; 1998 Nov; 339(21):1506-14. PubMed ID: 9819449
[TBL] [Abstract][Full Text] [Related]
16. High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: importance of disease status at transplant.
Crump M; Smith AM; Brandwein J; Couture F; Sherret H; Sutton DM; Scott JG; McCrae J; Murray C; Pantalony D
J Clin Oncol; 1993 Apr; 11(4):704-11. PubMed ID: 8478664
[TBL] [Abstract][Full Text] [Related]
17. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group.
Meyer RM; Gospodarowicz MK; Connors JM; Pearcey RG; Bezjak A; Wells WA; Burns BF; Winter JN; Horning SJ; Dar AR; Djurfeldt MS; Ding K; Shepherd LE; ;
J Clin Oncol; 2005 Jul; 23(21):4634-42. PubMed ID: 15837968
[TBL] [Abstract][Full Text] [Related]
18. [Clinical characteristics and therapy outcome in children with stage IV Hodgkin's lymphoma--the experience of two oncological centres].
Bień E; Stachowicz-Stencel T; Zawitkowska-Klaczyńska J; Adamkiewicz-Drozyńska E; Odój T; Połczyńska K; Mitura-Lesiuk M; Stefanowicz J; Sierota D; Szołkiewicz A; Birkholz D; Hennig M; Kowalczyk JR; Balcerska A
Med Wieku Rozwoj; 2006; 10(3 Pt 1):631-8. PubMed ID: 17317894
[TBL] [Abstract][Full Text] [Related]
19. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study. Société Francaise de Greffe de Moelle.
André M; Henry-Amar M; Pico JL; Brice P; Blaise D; Kuentz M; Coiffier B; Colombat P; Cahn JY; Attal M; Fleury J; Milpied N; Nedellec G; Biron P; Tilly H; Jouet JP; Gisselbrecht C
J Clin Oncol; 1999 Jan; 17(1):222-9. PubMed ID: 10458237
[TBL] [Abstract][Full Text] [Related]
20. High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy: results from the EBMT. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Sweetenham JW; Taghipour G; Milligan D; Blystad AK; Caballero D; Fassas A; Goldstone AH
Bone Marrow Transplant; 1997 Nov; 20(9):745-52. PubMed ID: 9384476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
